Prof. Aloke K. Dutta Department of Pharmaceutical Sciences Wayne State University Room number: 3128 259 Mack Avenue Detroit,MI 48202 Email: firstname.lastname@example.org Phone: 313-577-1064 Fax: 313-577-2033
Our research integrates medicinal chemistry, neuropharmacology, computational chemistry and molecular biology not only to understand the mechanism of action of novel CNS active molecules but also to advance promising leads to preclinical studies. We focus on discovery of novel CNS drugs to explore their potential therapeutic applications in several neuro-disorders like Parkinson’s disease (PD), depression and drug addiction. Specifically, novel molecules which are designed through rational drug design and computational studies, are being developed routinely to target monoamine transporters and receptors systems either selectively or non-selectively to produce desired pharmacological response. In PD research area we are focused on development of multifunctional molecules to produce disease modifying neuroprotective treatment agents. In this regard, we have been developing multifunctional D2/D3 DA agonists by incorporating metal chelation and anti-oxidant properties along with inhibitory activity against amyloidogenic proteins like alpha-synuclein and amyloid beta proteins aggregation in these molecules to address complex pathogenesis of PD including oxidative stress. Our overall goal in this project is not only to address symptomatic (relieving motor dysfunction) factor of the disease but also to produce disease modifying neuroprotective effects to slow or stop the progression of the disease. In the depression area, we have developed novel triple uptake inhibitors as promising new generation antidepressants addressing anhedonia in MDD. One of our main thrust in our research is to develop multifunctional molecules as a novel approach to CNS drug discovery and development. Our research is supported by multiple NIH R01 grants.
NOVEL NEUROPROTECTIVE THERAPY FOR NEURODEGENERATIVE DISEASES
PROJECT # 1:
Pathogenesis of PD and neurodegeneration in general is complex. Growing body of literature suggests that suitable multifunctional drugs might be more effective to act as disease modifying agents than drugs that target a single functional component. In this regard, our multifunctional drug design approach combines dopamine D2/D3 agonist property along with other multifunctional pharmacological properties targeting complex pathogenic factors of PD. We hypothesize that such drugs will have the potential to slow or stop the disease progression while being symptomatically beneficial in alleviating motor dysfunction.
Effect of oxidative stress is strongly implicated in PD neurodegeneration. In this regard, we have been developing polyfunctional dopamine agonist molecules, which, along with their agonist activity, also should complex to metal ion like iron. Role of Iron, alpha synuclein protein aggregation and oxidative stress have been implicated strongly in the pathogenesis of PD. Our multifunctional properties include antioxidant activity, iron chelation activity, increasing cellular GSH/ catalase level, increasing UPS level and inhibiting alpha-synuclein protein aggregation.We have developed a novel molecular template based on a hybrid drug development approach. Further SAR studies led to the development of a series of agonist molecules from this novel template. Recently, we published papers demonstrating neuroprotective property of lead multifunctional potent D2/D3 agonists (J. Neurosci. Res. 88: 2513–2523, 2010, ACS Chem. Neurosci. 4 (10), pp 1382–1392, 2013, J. Neurochemistry, Volume 131, Issue 1, 74–85, 2014, Neurotoxicity Research, 4, 302-18, 2015). In parallel, we have been designing multifunctional D2/D3 and D3 preferring agonists by incorporating metal chelation and anti-oxidant properties along with inhibitory activity against alpha-synuclein and amyloid beta proteins aggregation and toxicities in these molecules to address complex pathogenesis of PD including oxidative stress. We have recently published articles on iron binding D2/D3 agonists to demonstrate validity of our proof of concept (J. Med. Chem. 53, 2114–2125, 2010; ChemMedChem. 6, 991-5, 2011, ACS Chem Neurosci, 8(4):723-730, 2017; Neuropharmacology, 123, 88-99, 2017). We have also recently published articles demonstrating effect of multifunctional D2/D3 agonists in modulation of alpha synuclein protein aggregation and toxicity ( ACS Chem. Neurosci., 2014, 5 (8), pp 700–717; Scientific Reports 6, Article number: 38510 2016; Neuropharmacology, 123, 88-99, 2017).
Figure 1: Possible mode of actions of multifunctional drugs
Figure 2: Mechanism of multifunctional drug action
Therapeutic potential of selective D3-molecules in the treatment of cocaine addiction and toxicity are being explored. The application of selective D3 antagonists in the atypical treatment of Psychotic disorders will also be investigated.
This research is funded by NINDS.
Recent Selected Publications in this project:
1. Chao Li, S. Biswas, Xingang Li, Feifei Luo, *A. K. Dutta2, *Weidong Le1; Novel multifunctional drug D-264 for Parkinson’s disease: Evidence of neuroprotective property in PD animal models induced by MPTP and lactacystin. J. Neurosci. Res. 88: 2513–2523, 2010.
2. Balaram Ghosh,a Tamara Antonio,,c Maarten E. A. Reithb, and Aloke K. Duttaa Discovery of 4-(4-(2-((5-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)-ethyl)piperazin-1-yl)quinolin-8-ol and its analogues with dopamine D2/D3 agonists activity with a capacity to bind to iron: potential application in neuroprotective therapy for Parkinson’s Disease. J. Med. Chem. 53, 2114–2125, 2010.
3. Dopamine D2/D3 agonist with potent iron chelation, antioxidant and neuroprotective properties: Potential implication in symptomatic and neuroprotective treatment of Parkinson’s disease. Sanjib Gogo, Tamara Antonio, Subramanian Rajagopalan, Maarten Reith, Julie Andersen, Aloke K. Dutta*. ChemMedChem. 6, 991-5, 2011.
D-512 and D-440 as novel multifunctional dopamine
agonists: Characterization of neuroprotection properties and evaluation of in
vivo efficacy in a Parkinson’s disease animal model. Soumava Santra, Liping Xu,
Mrudang Shah, Mark Johnson and Aloke Dutta. ACS Chem. Neurosci.,
4 (10), pp 1382–1392,
5. High affinity D2/D3 agonist D512 protects PC12 cells from 6-OHDA induced apoptotic cell death and rescued dopaminergic neurons in the MPTP mouse model of Parkinson’s disease. Mrudang Shah, Chandrasekhar Voshavar, Liping Xu, Subramanian Rajagopalan, Julie Andersen, Aloke Dutta. Journal of Neurochemistry. Volume 131, Issue 1, 74–85, 2014.
6. Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: Modulator of toxicity of Alpha synuclein aggregates. Gyan Modi, Chandrashekhar Voshavar, Mrudang Shah, Tamara Antonio, Maarten Reith, Aloke Dutta. ACS Chem. Neurosci., 2014, 5 (8), pp 700–717.
7. Assessment of protective role of multifunctional dopamine agonist D-512 against Oxidative stress produced by depletion of Glutathione in PC12 cells: Implication in neuroprotective therapy for Parkinson’s disease. Chandrasekhar Voshavar, Mrudang Shah, Liping Xu, Aloke Dutta. Neurotoxicity Research, 4, 302-18, 2015.
Inhibition of alpha-synuclein aggregation by
multifunctional dopamine agonists assessed by a novel
in vitro assay and an in vivo
Drosophila synucleinopathy model.
Deepthi Yedlapudi, Gnanada Joshi, Dan Luo, Sokol Todi,
Aloke K. Dutta. Scientific Reports
6, Article number: 38510 (2016).
8. Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model. Deepthi Yedlapudi, Gnanada Joshi, Dan Luo, Sokol Todi, Aloke K. Dutta. Scientific Reports 6, Article number: 38510 (2016). doi:10.1038/srep38510
A Novel Iron (II) Preferring Dopamine Agonist
Chelator as Potential Symptomatic and Neuroprotective Therapeutic agent for
Banibrata Das, Ashoka Kandegedara,
Liping Xu, Tamara Antonio, Timothy Stemmler,
Maarten E.A. Reith, Aloke K. Dutta. ACS Chem Neurosci, 8(4):723-730,
9. A Novel Iron (II) Preferring Dopamine Agonist Chelator as Potential Symptomatic and Neuroprotective Therapeutic agent for Parkinson’s Disease. Banibrata Das, Ashoka Kandegedara, Liping Xu, Tamara Antonio, Timothy Stemmler, Maarten E.A. Reith, Aloke K. Dutta. ACS Chem Neurosci, 8(4):723-730, 2017.
A novel iron (II) preferring dopamine agonist chelator D-607
significantly suppresses α-Syn- and MPTP-induced toxicities in vivo.
Gnanada S. Joshi, Liping Xu, Dan Luo, Sokol V. Todi,
Julie K. Andersen, Aloke K. Dutta.
Neuropharmacology, 123, 88-99, 2017.
10. A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-Syn- and MPTP-induced toxicities in vivo. Banibrata Das, Subramanian Rajagopalan, Gnanada S. Joshi, Liping Xu, Dan Luo, Sokol V. Todi, Julie K. Andersen, Aloke K. Dutta. Neuropharmacology, 123, 88-99, 2017.
D-512, a novel dopamine D2 /
D3 receptor agonist, demonstrates superior anti-parkinsonian efficacy over
ropinirole in parkinsonian rats. David Lindenbach, Banibrata Das,
Melissa M. Conti, Samantha Meadows, Aloke K.
Dutta, Christopher Bishop. British Journal of Pharmacology, 174(18):3058-3071,
11. D-512, a novel dopamine D2 / D3 receptor agonist, demonstrates superior anti-parkinsonian efficacy over ropinirole in parkinsonian rats. David Lindenbach, Banibrata Das, Melissa M. Conti, Samantha Meadows, Aloke K. Dutta, Christopher Bishop. British Journal of Pharmacology, 174(18):3058-3071, 2017.
TRIPLE UPTAKE INHIBTOR AS NOVEL MODULATORS OF DEPRESSION AND PAIN
PROJECT # 2
In this project, we have been developing via asymmetric synthesis process, novel asymmetric unique pyran templates as blockers for serotonin (SERT), norepinephrine (NET) and dopamine (DAT) transporters. Our initial work on development of asymmetric di- and tri-substituted pyran derivatives identified potent triple uptake inhibitors (TRI) as blocker of SERT, DAT and NET as well as selective dopamine-norepinephrine reuptake inhibitors (DNRI). Asymmetric synthesis methods have been developed by us to generate these novel molecules. Our central hypothesis in this project is to evaluate whether the inclusion of additional dopaminergic activity in these TUI will enhance their antidepressant activity as dopamine has been strongly linked to major depressive disorder (MDD). Some of our selected publications in this area are J. Med. Chem. 48, 4962-4971, 2005; EJP, 589, 73–79, 2008; EJP, 671, 39–44, 2011; ChemMedChem, 7(12):2093-100, 2012; Bioorganic & Medicinal Chemistry 22 (2014) 311–324). In one of our recent publications, we have demonstrated development of an orally active TRI (Plos One, 2014, 9, e113420). One of our important goals will be to study whether such novel TRI molecules can address anhedonia, a major unmet need in the current treatment of MDD, which accounts for their inefficacy. Thus, TRI can potentially serve as a new generation antidepressants by producing more desirable therapeutic profiles compared to the current existing drugs. Furthermore, in a recent Post-Traumatic Stress Disorder (PTSD) animal model study, we have shown one of the lead compounds, D-578, to reverse the PTSD effect and in that regard, it was more effective than currently approved SSRI Paroxetine. Our drug discovery effort in this project integrates studies, which include chemistry, in vitro and in vivo pharmacology, Positron Emission Tomography (PET) imaging and new generation animal depression models. I have been funded by a R01 (NIH/NIMH) grant based on this project.
Recent Publication on this Project:
1. Shijun Zhang, Fernando Fernandez, Stuart Hazeldine, Juan Zhen, Maarten E. A. Reith, and Aloke K. Dutta. J. Med. Chem. 49, 4239-4247, 2006.
2. Aloke Dutta, Balaram Ghosh, Swati Biswas and Maarten Reith. . Pharmacological characterization of D-161, a novel triple monoamine transporter blocker: Production of antidepressant-like action. European Journal of Pharmacology, 589, 73–79, 2008.
3. Further structure activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Identification of compounds with triple uptake inhibitory activity as potential antidepressant agents. Bhaskar Gopishetty, Stuart Hazeldine, Soumava Santra, Mark Johnson, Gyan Modi, Solav Ali, Juan Zhen, Maarten Reith Aloke Dutta. J. Med. Chem. 54, 2924-32, 2011.
4. The novel trisubstituted pyran derivative D-142 with triple monoamine reuptake inhibitory activity: potent antidepressant-like activity from animal models of depression studies. Aloke K. Dutta, Bhaskar Gopishetty, Sanjib Gogoi, Solav Ali, Juan Zhen, Maarten Reith. European Journal of Pharmacology, 671, 39–44, 2011.
5. Pharmacological and behavioral characterization of an orally active triple reuptake inhibitor D-473: Effects of drug on extracellular levels of dopamine, serotonin and norepinephrine. Aloke Dutta, Soumava Santra, Horrick Sharma, Chandrasekhar Voshavar, Liping Xu, Omar Mabrouk, Tamara Antonio, Maarten Reith. Plos One, 2014, 9, e113420.
Monoamine Transporters As Molecular Targets:
PROJECT # 3:
In this project, we are investigating rational design, synthesis and biological evaluation of potent and selective small molecules for their binding to the biogenic amines neurotransporter systems, specifically for the dopamine transporter (DAT) system. The DAT is a putative presynaptically located 12-transmembrane domain protein, which translocates extracellular dopamine into the nerve endings of DA neurons. The DAT is an important constituent of brain pathways that contribute to movement and behavioral reward. Analysis of these designed molecules in various in vitro binding assays is being carried out routinely to understand their mode of binding with the transporter molecules and to build Structure-Activity Relationship studies. One of our goals is to explore the potential use of these compounds as medicating agents for the treatment of cocaine and methamphetamine addiction and other neurological disorders. We are also engaged in developing of Single Photo Electron Computer Tomography (SPECT) and Positron Emission Tomography (PET) agents for imaging studies in the CNS, along with development of affinity and photo-affinity ligands as molecular probes to characterize the binding interaction with the receptors further at a molecular level to understand their functional properties. In this context, we are pursuing site directed mutagenesis study with the dopamine transporter mutants to discover point of interactions on the DAT molecule with our selective and potent ligands.
We already have generated a novel series of compounds, which were found to be very selective for the dopamine transporter system from in vitro studies and exhibited interesting in vivo activity. Currently, we are in the process of evaluating a selected DAT selective molecule in primate studies to evaluate its potential to modulate cocaine effect. This study was funded by NIH/NIDA.
1. Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing exocyclic hydroxyl group: Interaction with dopamine, serotonin and norepinephrine transporters. Manoj Mishra, Rohit Kolhatkar, Juan Zhen, Ingrid Parrington, Maarten E. A. Reith, Aloke K. Dutta. Bioorganic Medicinal Chemistry, 16, 2769-2778, 2008.
Prashant S. Kharkar, Angela Batman, Juan Zhen, Patrick M. Beardsley,
Maarten E. A. Reith and
Maarten E. A. Reith and
Aloke K. Dutta. Synthesis and biological characterization of (3R,4R)-4-(2-(benzhydryloxy)ethyl)-1-((R)-2-hydroxy-2-phenylethyl)-piperidin-3-ol and its stereoisomers for monoamine transporters. ChemMedChem, 1075-85, 2009.
3. Angela Batman, Aloke Dutta, Patrick Beardsley. Characterising the Behavioural Effects of D-84, a selective DAT inhibitor: Potential as a Replacement Therapy for Cocaine Dependence. EJP, 648, 127–132, 2010.
Copyright © 2012 Dutta Lab, Wayne State University. All rights reserved.
Last Updated 11/07/2017. Designed by Dr. Soumava Santra/Dr. Banibrata Das and Maintained by Prof. Aloke K. Dutta